ArticleInternational journal of clinical and experimental medicine2015
Expression of Yes-associated protein in liver cancer and its correlation with clinicopathological features and prognosis of liver cancer patients.
Article in International journal of clinical and experimental medicine, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 3 syntheses or guidelines pooled it, 16 citations in OpenAlex.
- Pooled it
- YAP1 overexpression is associated with poor prognosis of breast cancer patients and induces breast cancer cell growth by inhibiting PTEN.FEBS open bio · 2019Pooled it
- Overexpression of Yes-associated protein and its association with clinicopathological features of hepatocellular carcinoma: A meta-analysis.Liver international : official journal of the International Association for the Study of the Liver · 2017Pooled it
- Research progress in role of Hippo signaling pathway in diagnosis and treatment for hepatocellular carcinoma.Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences · 2021Article
- Transitional cell carcinoma matrix stiffness regulates the osteopontin and YAP expression in recurrent patients.Molecular biology reports · 2021Article
- Shikonin regulates invasion and autophagy of cultured colon cancer cells by inhibiting yes-associated protein.Oncology letters · 2019Article
- Antiproliferative and Antimigratory Effects of a Novel YAP-TEAD Interaction Inhibitor Identified Using in Silico Molecular Docking.Journal of medicinal chemistry · 2019Article
- Curcumin Induces Autophagy via Inhibition of Yes-Associated Protein (YAP) in Human Colon Cancer Cells.Medical science monitor : international medical journal of experimental and clinical research · 2018Article
- MicroRNA-185 suppresses pancreatic cell proliferation by targeting transcriptional coactivator with PDZ-binding motif in pancreatic cancer.Experimental and therapeutic medicine · 2018Article
- Yes-associated protein: A novel molecular target for the diagnosis, treatment and prognosis of hepatocellular carcinoma.Oncology letters · 2017Article
- Subtractive Cell-SELEX Selection of DNA Aptamers Binding Specifically and Selectively to Hepatocellular Carcinoma Cells with High Metastatic Potential.BioMed research international · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo investigate the expression of Yes-associated protein (YAP) in liver cancer and its correlation with clinicopathological features and prognosis of liver cancer patients.
methodsA total of 95 patients receiving surgery due to liver cancer were recruited.
resultsIn 95 liver cancers, YAP expression was significantly higher than that in adjacent normal tissues. In addition, of liver cancers, 14.7% was negative for YAP (14/95), 29.5% (28/95) weakly positive, 21.1% (20/95) positive and 34.7% (33/95) strong positive, and low expression and high expression were observed in 44.2% (42/95) and 55.8% (53/95) of liver cancers, respectively. Of adjacent normal tissues, 13.7% (13/95) were negative or weakly positive for YAP. The mean survival time of patients with high YAP expression was significantly longer than that of patients with low YAP expression (Log-rank = 9.206, P < 0.01). Univariate analysis showed portal vein thrombosis (P < 0.01), metastasis (P < 0.01), American Joint Committee on Cancer Staging (AJCC) stage (P < 0.01), alpha fetoprotein (AFP) (P < 0.01) and high YAP expression (P < 0.01) were factors affecting the overall survival of liver cancer patients. However, multivariate analysis showed metastasis (P < 0.01) and high YAP expression (P < 0.01) were independent risk factors of overall survival of liver cancer patients.
conclusionYAP expression increases significantly in liver cancer and it may be involved in the occurrence and development of liver cancer. YAP expression is an independent risk factor affecting the overall survival of liver cancer patients.
Indexed as
Identifiers
25785096PMC4358551W38237341What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.